Sort   by:  
 Page size 
UnknownPhase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Not available
S-EPMC4874204 | biostudies-literature
UnknownHealth-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Not available
S-EPMC5791840 | biostudies-literature
UnknownSelective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Not available
S-EPMC6905485 | biostudies-literature
UnknownMeasurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Not available
S-EPMC7873068 | biostudies-literature
UnknownFinal analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Not available
S-EPMC11136961 | biostudies-literature
UnknownExtrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
Not available
S-EPMC10447673 | biostudies-literature
UnknownDaratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Not available
S-EPMC6676132 | biostudies-literature
UnknownComparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Not available
S-EPMC5302948 | biostudies-literature
UnknownIntrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Not available
S-EPMC12281119 | biostudies-literature
UnknownSex differences in outcomes in multiple myeloma.
Not available
S-EPMC8182969 | biostudies-literature
Sort   by:  
 Page size